Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Interest & Investment Income (2019 - 2025)

Harvard Bioscience (HBIO) has disclosed Interest & Investment Income for 7 consecutive years, with -$966000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 12.85% to -$966000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.4 million, a 8.32% decrease, with the full-year FY2024 number at -$3.2 million, up 10.64% from a year prior.
  • Interest & Investment Income was -$966000.0 for Q3 2025 at Harvard Bioscience, down from -$791000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of -$373000.0 in Q3 2021 to a low of -$974000.0 in Q1 2023.
  • A 5-year average of -$707736.8 and a median of -$791000.0 in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 69.42% in 2021, then tumbled 153.65% in 2023.
  • Harvard Bioscience's Interest & Investment Income stood at -$379000.0 in 2021, then tumbled by 137.47% to -$900000.0 in 2022, then rose by 11.78% to -$794000.0 in 2023, then decreased by 7.43% to -$853000.0 in 2024, then decreased by 13.25% to -$966000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Interest & Investment Income are -$966000.0 (Q3 2025), -$791000.0 (Q2 2025), and -$802000.0 (Q1 2025).